Notice of Results and Investor Presentation

RNS Number : 6269L

Instem plc

14 September 2021

 

Instem plc

("Instem")

Notice of Results and Investor Presentation

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, will announce results for the half year ended 30 June 2021 on Monday 27 September 2021.  

Investor Presentation: 4.00pm, Monday 27 September

Management will be providing a presentation and hosting an Investor Q&A session on the results and future prospects, as well as the recent acquisition of PDS Pathology Data Systems Ltd on the day of results, at 4.00pm. Investors can sign up for free and add to attend the presentation via the following link: https://www.investormeetcompany.com/instem-plc/register-investor

Questions can be submitted pre-event and at any time during the live presentation via the Investor Meet Company Platform.

Analyst Presentation: 11:30am, Monday 27 September

Management will be hosting a presentation via web conference on the day of the results at 11.30am. Analysts wishing to join should register their interest by emailing [e-mail]   or by telephoning 020 7933 8780.

For further information, please contact:

Instem plc	Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated Adviser & Broker)	[phone]
Peter Steel Alex Bond Rachel Hayes
Walbrook Financial PR	[phone]
Tom Cooper	[e-mail]
Nick Rome Nicholas Johnson

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study ManagementRegulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

To learn more about Instem solutions and its mission, please visit  www.instem.com

 

END

 

 

NORSFDFWDEFSESU